PROC
Procaps Group S.A.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · LU
$1.01
+0.00%Income statement
| Metric | TTM | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 414.1M | 409.9M | 409.7M | 331.5M | 324.8M |
| Cost of Revenue | 186.2M | 170.4M | 174.0M | 140.2M | 142.3M |
| Gross Profit | 227.9M | 239.6M | 235.7M | 191.3M | 182.5M |
| Operating Expenses | |||||
| R&D Expense | 2.7M | — | 3.1M | — | — |
| SG&A Expense | 194.2M | 199.5M | 165.2M | 128.3M | 145.1M |
| General & Admin Expense | 100.7M | 105.9M | 82.2M | 58.6M | 60.3M |
| Selling & Marketing Expense | 93.5M | 93.6M | 83.1M | 69.6M | 84.8M |
| Other Expenses | 13.1M | — | (72.1M) | (844.0K) | 273.0K |
| Total Operating Expenses | 194.2M | 187.2M | 165.2M | 128.3M | 145.1M |
| Cost and Expenses | 380.4M | 357.6M | 339.3M | 268.4M | 287.4M |
| Operating Income (EBIT) | 93.8M | 52.3M | (5.3M) | 60.4M | 36.3M |
| Non-Operating | |||||
| Interest Income | 8.1M | — | 85.3M | 52.6M | 41.5M |
| Interest Expense | 64.0M | 25.8M | 85.3M | 52.6M | 41.5M |
| Net Interest Income | (87.5M) | (25.8M) | (89.0M) | (54.5M) | (43.0M) |
| Other Non-Op Income/Expense | (4.4M) | 386.0K | (156.9M) | (59.5M) | (46.2M) |
| Non-Operating Income (excl Interest) | (56.8M) | (26.1M) | 78.2M | 6.9M | 4.7M |
| EBT (Pre-Tax Income) | 67.8M | 52.7M | (87.2M) | 849.0K | (10.0M) |
| Income Tax Expense | 15.5M | 10.2M | 13.7M | 11.3M | 7.0M |
| Bottom Line | |||||
| Net Income | 52.2M | 42.5M | (100.9M) | (10.4M) | (17.0M) |
| Earnings from Cont. Ops | 52.2M | 42.5M | (100.9M) | (10.4M) | (17.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 52.2M | 42.5M | (100.9M) | 500.5K | (17.0M) |
| Per Share | |||||
| Basic EPS | $0.52 | $0.42 | ($1.03) | ($0.09) | ($0.15) |
| Diluted EPS | $0.52 | $0.42 | ($1.03) | ($0.09) | ($0.15) |
| Revenue Per Share | $4.04 | $4.05 | $4.18 | $2.94 | $2.88 |
| Shares | |||||
| Basic Shares Outstanding | 102.4M | 101.1M | 97.9M | 112.8M | 112.8M |
| Diluted Shares Outstanding | 102.4M | 101.1M | 98.1M | 112.8M | 112.8M |
| Profitability Metrics | |||||
| EBITDA | 120.2M | 95.3M | 6.6M | 70.0M | 48.0M |
| D&A | 17.5M | 16.8M | 15.1M | 16.5M | 16.5M |
| EBIT | 129.0M | 78.5M | (8.5M) | 53.5M | 31.6M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2023